Infantile Severe Myoclonic Epilepsy
Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment
Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership
Stoke Therapeutics Announces Global Phase 3 EMPEROR Study Design for Zorevunersen in Dravet Syndrome
Dravet syndrome, zorevunersen, Phase 3 trial, EMPEROR study, seizure reduction, cognitive improvement, regulatory alignment
Ovid Halts Preclinical Work and IV Seizure Program Following Soticlestat’s Phase 3 Setbacks
Ovid Therapeutics, soticlestat, Phase 3 trials, Dravet syndrome, Lennox-Gastaut syndrome, preclinical work, IV seizure program, Takeda Pharmaceutical
Stoke Therapeutics Advances Dravet Syndrome Drug to Phase III Trials After FDA Lifts Partial Clinical Hold
Stoke Therapeutics, Dravet syndrome, Phase III trials, FDA, zorevunersen, SCN1A activator, orphan drug designation, rare pediatric disease designation
Takeda’s Soticlestat Misses Main Goal in Two Pivotal Epilepsy Studies
Soticlestat, Takeda, Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Phase 3 Trials, Seizure Frequency
Harmony Pharmaceuticals Expands into Rare Genetic Epilepsies with Acquisition of Epygenix Therapeutics
Harmony Pharmaceuticals, Epygenix Therapeutics, rare genetic epilepsies, acquisition, treatment, research, development, collaboration, genetic mutations, Dravet syndrome, CDK-like kinase inhibitors
Groundbreaking Data Revealed for Genetic Epilepsy Drug STK-001 by Stoke Therapeutics, Exhilarating Investors
Stoke Therapeutics, STK-001, Genetic Epilepsy Drug, Dravet Syndrome, Antisense Oligonucleotide, Seizure Reduction, Positive Clinical Trial Data, Investor Enthusiasm